Geron (GERN) director Dawn Carter Bir awarded 220,000 stock options

Rhea-AI Filing Summary

Geron Corp director Dawn Carter Bir received a new stock option grant. On 2026-05-20, she was awarded options to acquire 220,000 shares of Geron common stock at an exercise price of $1.2600 per share, with no cost for the grant itself.

The option covers 220,000 underlying common shares and expires on 2036-05-19. According to the terms, it will vest and become exercisable in full on the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date, provided she maintains continuous service with Geron through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bir Dawn Carter

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	220,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 220,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 220,000 options Exercise price: $1.2600 per share Underlying shares: 220,000 shares +1 more

4 metrics

Option grant size 220,000 options Stock Option (right to buy) granted on May 20, 2026

Exercise price $1.2600 per share Exercise price for underlying Geron common stock

Underlying shares 220,000 shares Common Stock underlying the new option grant

Option expiration May 19, 2036 Expiration date of the stock option grant

Key Terms

Stock Option (right to buy), exercise price, expiration date, continuous service

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.2600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-19T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

continuous service financial

"subject to the Reporting Person's continuous service with the Issuer"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bir Dawn Carter

(Last) (First) (Middle)

C/O GERON CORPORATION

919 EAST HILLSDALE BOULEVARD, SUITE 250

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GERON CORP [ GERN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.26	05/20/2026		A		220,000		(1)	05/19/2036	Common Stock	220,000	$0	220,000	D

Explanation of Responses:

1. This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.

	/s/ Michelle Robertson, Attorney-in-Fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Geron (GERN) report for Dawn Carter Bir?

Geron reported a stock option grant to director Dawn Carter Bir. She received options for 220,000 shares of common stock, with an exercise price of $1.2600 per share, as part of her equity-based compensation on May 20, 2026.

How many Geron (GERN) shares are covered by Dawn Carter Bir’s new option?

The new stock option granted to Dawn Carter Bir covers 220,000 shares of Geron common stock. These options give her the right to buy that number of shares at a fixed $1.2600 exercise price if and when the options vest and are exercised.

What is the exercise price and expiration date of Dawn Carter Bir’s Geron options?

The option has an exercise price of $1.2600 per share and expires on May 19, 2036. She may exercise the options after they vest, as long as she meets the continuous service conditions through the applicable vesting date.

When do Dawn Carter Bir’s Geron (GERN) stock options vest?

The options will vest and become exercisable 100% on the earlier of Geron’s next annual stockholder meeting or the first anniversary of the grant date. Vesting is contingent on her continuous service with the company through that chosen vesting date.

Is Dawn Carter Bir’s Geron stock option grant an open-market purchase or a compensation award?

The filing describes this transaction as a grant or award acquisition, not an open-market purchase. The options were issued at no cost as part of her director compensation, with a fixed $1.2600 exercise price for the underlying common shares.